Fig. 3

Summary of outcomes of subgroup analyses for NOACs in patients with AF and diabetes. ^aIndicated by a history of stroke, transient ischaemic attack or SE, or ≥ 2 of the following risk factors; heart failure or a left ventricular ejection fraction of ≤ 35, hypertension, age of ≥ 75 years or diabetes (CHADS₂ score of ≥ 2). ^bIndicated by a history of stroke, transient ischaemic attack or SE, or systematic heart failure within prior 3 months or a left ventricular ejection fraction of ≤ 40%, hypertension requiring pharmacological treatment, age of ≥ 75 years or diabetes. ^cIndicated by a history of stroke or transient ischaemic attack, New York Heart Association class II or higher heart failure symptoms ≤ 6 months before screening, a left ventricular ejection fraction of ≤ 40%, age of ≥ 75 years or age 65–74 years with diabetes, hypertension or coronary artery disease. ^dHR and 95% CI not reported. AF, atrial fibrillation; CI, confidence interval; CHADS₂, Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke or transient ischaemic attack (2 points); CRNM, clinically relevant non-major bleeding; HR, hazard ratio; ICH, intracranial haemorrhage; ISTH, International Society on Thrombosis and Haemostasis; NOAC, non-vitamin K antagonist oral anticoagulant; NVAF, non-valvular atrial fibrillation; SD, standard deviation; SE, systemic embolism